OCREVUS Drug Profile

Summary for Tradename: OCREVUS

High Confidence Patents:	3
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for OCREVUS

Recent Clinical Trials for OCREVUS

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Amgen	PHASE3
National Institute of Allergy and Infectious Diseases (NIAID)	Phase 4
Autoimmunity Centers of Excellence (ACE)	Phase 4

See all OCREVUS clinical trials

Pharmacology for OCREVUS

Mechanism of Action	CD20-directed Antibody Interactions
Established Pharmacologic Class	CD20-directed Cytolytic Antibody
Chemical Structure	Antibodies, Monoclonal Antibodies, Monoclonal, Humanized

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for OCREVUS Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for OCREVUS Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Genentech, Inc.	OCREVUS	ocrelizumab	Injection	761053	7,799,900		DrugPatentWatch analysis and company disclosures
Genentech, Inc.	OCREVUS	ocrelizumab	Injection	761053	8,562,992		DrugPatentWatch analysis and company disclosures
Genentech, Inc.	OCREVUS	ocrelizumab	Injection	761053	9,683,047		DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for OCREVUS Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Genentech, Inc.	OCREVUS	ocrelizumab	Injection	761053	10,016,338	2036-12-20	Patent claims search
Genentech, Inc.	OCREVUS	ocrelizumab	Injection	761053	10,035,848	2035-01-08	Patent claims search
Genentech, Inc.	OCREVUS	ocrelizumab	Injection	761053	10,093,732	2035-11-05	Patent claims search
Genentech, Inc.	OCREVUS	ocrelizumab	Injection	761053	10,111,968	2036-08-10	Patent claims search

Market Dynamics and Financial Trajectory for OCREVUS

Last updated: April 8, 2026

What are the key market drivers for OCREVUS?

OCREVUS (ocrelizumab), developed by Roche, is a monoclonal antibody targeting CD20-positive B cells used primarily for multiple sclerosis (MS) and certain autoimmune conditions. The drug’s market strength hinges on its approval status, competitive positioning, and expanding indications.

Market size and growth potential

• The global multiple sclerosis market was valued at approximately USD 21 billion in 2021.
• It is projected to grow at a compound annual growth rate (CAGR) of 3.9% through 2028 [1].
• OCREVUS accounts for a significant share, with peak sales projected between USD 8–10 billion by 2025, driven by expanding approvals and dosing convenience.

Key growth drivers

• Increasing MS prevalence: Nearly 2.8 million people live with MS globally, with prevalence increasing in regions like Asia-Pacific and Latin America.
• Expansion into primary progressive MS (PPMS): FDA approved OCREVUS for PPMS in 2017, a segment with limited treatment options.
• Patient preference for infusion therapies: OCREVUS offers biannual dosing, improving compliance versus higher-frequency regimens.

Market challenges

• Competition from other anti-CD20 therapies: Rituximab, ofatumumab, and newer agents like Zeposia (ozanimod) and Mayzent (siponimod).
• Biosimilar threats: Although biosimilars are not yet prevalent in biologics for MS, patent expiry risks exist.
• Safety concerns: Risks of infections and potential malignancy influence prescriber and payer decisions.

How does OCREVUS’s competitive position influence its financial trajectory?

Market share trends

• Roche reported OCREVUS sales of USD 4.3 billion in 2022, reflecting rapid adoption and robust demand.
• Estimated to hold approximately 60% of the MS biologics market share in North America and Europe.

Pricing strategies and reimbursement

• Average wholesale price (AWP) per infusion: USD 7,500–USD 8,000.
• Reimbursement coverage varies globally, with payer negotiations influencing net prices.
• Roche's strategic partnerships facilitate market access, especially in emerging markets.

Sales forecasts and revenue projections

Year	Projected Sales (USD billion)	Assumptions
2023	4.5	Continued expansion into PPMS and vertical integration
2024	4.9	Market penetration stabilizes, new indications possible
2025	8.0–10.0	Peak sales with broad global adoption

• Sales growth depends on new indications, improved safety profiles, and sustained demand in established markets.

What are regulatory and pipeline factors affecting OCREVUS?

Regulatory milestones

• In 2017, FDA approved OCREVUS for RMS and PPMS.
• EMA approved for relapsing and primary progressive forms.
• Additional approvals are underway to extend indications, including pediatric MS.

Pipeline and new formulations

• Roche is testing subcutaneous formulations aiming to improve convenience.
• Ongoing trials for other autoimmune diseases, including neuromyelitis optica.
• Development of biosimilars may impact long-term pricing and market share.

How does the evolving landscape affect long-term financial prospects?

• Patent expiry is anticipated after 2029, with biosimilar entry potentially reducing prices.
• Market expansion into pediatric MS, neuromyelitis optica, and other autoimmune conditions presents upside.
• Competitive pressures from oral therapies may challenge OCREVUS's market dominance.

Key Takeaways

• OCREVUS remains a dominant biologic for relapsing and primary progressive MS, with sales surpassing USD 4 billion annually.
• Market growth hinges on expanded indications, geographic reach, and pipeline innovations.
• Competitive dynamics and impending biosimilar entries could pressure pricing and margins post-2029.
• Roche’s strategic focus on regulatory approvals and formulation improvements supports sustained revenue growth.
• Long-term profitability depends on market share retention amid growing competition and patent expirations.

FAQs

1. When will patent expiry impact OCREVUS’s sales?

Patent expiration is expected around 2029–2030, with biosimilar competition likely to influence pricing and market share.

2. What are the main competitors to OCREVUS?

Rituximab (used off-label in MS), ofatumumab (approved for MS), newer oral agents like Zeposia and Mayzent, and upcoming biosimilars.

3. How does the approval of OCREVUS for PPMS influence its market?

It broadens its addressable patient population, especially since PPMS has limited treatment options, boosting long-term revenue potential.

4. What pipeline developments could impact OCREVUS’s financial trajectory?

Subcutaneous formulations, new autoimmune indications, and biosimilar entries are critical factors.

5. How do reimbursement policies affect OCREVUS sales?

Reimbursement negotiations and formulary placements influence access and net pricing, particularly in cost-sensitive markets.

References

[1] MarketsandMarkets. (2022). Multiple Sclerosis Market Forecast. https://www.marketsandmarkets.com